<DOC>
	<DOCNO>NCT01083667</DOCNO>
	<brief_summary>The objective study evaluate safety , tolerability effect SOD1 level pyrimethamine patient familial amyotrophic lateral sclerosis .</brief_summary>
	<brief_title>SOD1 Inhibition Pyrimethamine Familial Amyotrophic Lateral Sclerosis ( ALS )</brief_title>
	<detailed_description>Amyotrophic lateral sclerosis ( ALS ) neurodegenerative disease cause relentlessly progressive weakness arm , legs respiratory muscle uniformly fatal . There approximately 30,000 patient living ALS United States . There treatment . The cause uncertain patient . However , 3 % patient ( &lt; 1000 number ) familial form ALS ( FALS ) , phenotypically identical sporadic illness , cause mutation gene cod free radical scavenge enzyme copper/zinc superoxide dismutase ( SOD1 ) . Inserting SOD1 mutant gene mouse cause develop disease closely resembling ALS . Inhibiting expression SOD1 gene prevents animal develop disease . Increasing decrease number mutate gene proportionately speed slow progression disease . Therefore , reduce SOD1 level patient SOD1 associate FALS may promise therapeutic approach . Through extensive vitro screen program medication ability reduce SOD1 level , several molecule reduce SOD1 protein level know . One potent molecule pyrimethamine , FDA approve medication use treatment malaria toxoplasmosis . Pyrimethamine dramatically reduce SOD1 level mice preliminary study show similar finding human . Our study 's primary objective determine familial ALS patient take pyrimethamine show decline SOD1 level CSF 15 % . We also determine SOD1 pyrimethamine present blood SOD-1 level decline course study . We also evaluate safety tolerability pyrimethamine patient FALS . Secondary objective determine dose optimization maximal SOD1 level reduction . We also assess feasibility proceed phase II/III study use pyrimethamine . Using futility methodology patient treat pyrimethamine compare historical control , 40 patient mild moderate FALS SOD1 mutation receive 75 mg pyrimethamine 36 week . A change 15 % slope decline deem significant power 80.7 percent . Change ALS-FRS quality life also measure . A clinical effect realize patient FALS associate SOD1 mutation may serve important foundation toward find treatment sporadic ALS .</detailed_description>
	<mesh_term>Sclerosis</mesh_term>
	<mesh_term>Motor Neuron Disease</mesh_term>
	<mesh_term>Amyotrophic Lateral Sclerosis</mesh_term>
	<mesh_term>Pyrimethamine</mesh_term>
	<criteria>Subjects definite , probable , laboratory support probable ALS eligible . 1 . ALS diagnose probable , laboratory support probable definite accord World Federation Neurology El Escorial criterion [ Brooks et al . 2000 ] 2 . Age 18 old 3 . Capable provide informed consent comply trial procedure 4 . SOD1 mutation confirmation study team 5 . Not take Riluzole ( Rilutek ) stable dose 30 day 6 . Not take Coenzyme QR10R stable dose brand 30 day 7 . Absence exclusion criterion 1 . History evidence malabsorption syndromes 2 . Exposure experimental agent within 30 day onset protocol 3 . Women pregnant plan become pregnant 4 . Women childbearing potential practicing contraception 5 . Women breastfeed 6 . Enrollment another research study within 30 day trial 7 . Alcoholism 8 . Patients take phenytoin ( Dilantin ) therapy affect folate level 9 . Dementia ( MMSE &lt; 22 ) 10 . Seizure disorder 11 . Folate deficiency 12 . Megaloblastic anemia 13 . Cardiovascular disorder/arrhythmia 14 . Impaired kidney function , define creatinine level 2.5 x ULN 15 . Impaired liver function , define AST ALT 3 X ULN 16 . Advanced ALS patient , define following : forced vital capacity &lt; 60 % ( use BIPAP allow ) ; tracheostomy ; mechanical ventilation 17 . Use following medication : cytosine , arabinoside , methotrexate , daunorubicin , sulfonamide , zidovudine , lorazepam , coumadin , sulfamethoxazole , trimethoprim 18 . Patients take Lithium within 30 day trial 19 . Incapable provide informed consent comply trial procedure</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>August 2016</verification_date>
	<keyword>ALS</keyword>
	<keyword>Familial ALS</keyword>
	<keyword>SOD1 Gene Mutation</keyword>
</DOC>